Illumina (NASDAQ:ILMN) Issues Quarterly Earnings Results, Beats Expectations By $0.26 EPS

Illumina (NASDAQ:ILMN) released its quarterly earnings data on Thursday. The life sciences company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.36 by $0.26, FiscalAI reports. The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The firm’s revenue was up 4.2% compared to the same quarter last year. During the same period last year, the company posted $1.34 earnings per share.

Here are the key takeaways from Illumina’s conference call:

• Strong Q3 performance and raised guidance: Rest-of-world organic revenue grew approximately 5%, operating margin reached 25%, and adjusted EPS was $1.44, ahead of expectations. Illumina raised full-year 2026 revenue guidance to $4.64–$4.66 billion and EPS guidance to $5.40–$5.45.
• Clinical demand and NovaSeq X placements remain robust: The company placed more than 80 NovaSeq X instruments in Q3, with clinical sequencing consumables growing 14% year over year. Illumina said the expanding installed base should support consumables revenue for years and expects clinical consumables growth in the mid-teens for 2026.
• Research and applied sequencing consumables declined 6% in the rest of the world, although management said activity appears to be stabilizing. The NovaSeq X transition is largely complete in research markets, while clinical conversion is expected to reach roughly 80%–85% and continue creating pricing headwinds, though less so in 2027.
• Margins and cash generation improved: Q3 gross margin was 69.4% and free cash flow was $378 million. Illumina expects approximately 23.6% operating margin for full-year 2026 and plans to continue opportunistic share repurchases, with about $1.8 billion remaining under its authorization.
• AI, multi-omics, and data initiatives are emerging growth opportunities: Illumina reported growing interest in its Billion Cell Atlas and BioInsight platform, including from GSK, and expects these offerings to become more visible in the financial results around 2027. Management believes multi-omics and AI-driven biological datasets could provide upside beyond its high-single-digit long-term growth framework, though the timing and scale remain uncertain.

Illumina Trading Up 0.4%

NASDAQ:ILMN opened at $290.06 on Friday. The firm has a market capitalization of $43.80 billion, a P/E ratio of 56.08, a P/E/G ratio of 4.09 and a beta of 1.41. The business has a 50 day simple moving average of $248.84 and a 200 day simple moving average of $175.73. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. Illumina has a 12-month low of $94.00 and a 12-month high of $309.35.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina reported non-GAAP earnings of $1.44 per share, above the $1.36 analyst consensus and up from $1.34 a year earlier. The company also reported quarterly net income of $220 million. Illumina Q3 Earnings Beat Estimates
• Positive Sentiment: Full-year revenue guidance of approximately $4.65 billion at the midpoint was modestly above analysts’ expectations, suggesting management remains confident in demand for its sequencing platforms and consumables. Illumina Reports Third-Quarter Results
• Neutral Sentiment: Analyst reaction was cautious: Robert W. Baird maintained a Hold rating. Broader industry reports continue to project strong growth in sequencing, genomic screening and related clinical markets, but these reports do not represent new Illumina contracts or company-specific revenue. Baird Maintains Hold on Illumina
• Negative Sentiment: Revenue rose 4.2% year over year to about $1.13 billion, below Wall Street’s roughly $1.15 billion expectation. The top-line miss appears to have outweighed the earnings beat, raising concerns about near-term growth momentum. Illumina Reports Sales Below Estimates
• Negative Sentiment: Investor expectations were elevated after a strong run in the shares, making the revenue miss more consequential. Quiver Quantitative also reported substantial insider selling in recent months, although that activity was not part of the quarterly release and may reflect portfolio or compensation-related transactions. Why Illumina Stock Is Up Today

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ILMN shares. JPMorgan Chase & Co. increased their target price on Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. TD Cowen boosted their price target on Illumina from $210.00 to $270.00 and gave the company a “hold” rating in a report on Tuesday, October 13th. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research report on Sunday, October 11th. Evercore restated an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Finally, UBS Group upgraded Illumina from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $135.00 to $260.00 in a research note on Wednesday, September 9th. Ten research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $234.41.

Insider Buying and Selling at Illumina

In other Illumina news, Director Keith Meister sold 119,501 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $218.40, for a total value of $26,099,018.40. Following the sale, the director directly owned 770,350 shares in the company, valued at approximately $168,244,440. This trade represents a 13.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Christensen Wedel sold 1,033 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,061,235 shares of company stock worth $436,356,102 over the last ninety days. 2.90% of the stock is owned by corporate insiders.

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.